![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Abbott Secures EUA for COVID-19 Combination Test
Abbott Secures EUA for COVID-19 Combination Test
![abbott-logo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/abbott-logo.gif?t=1614806228&width=430)
Abbott has received Emergency Use Authorization (EUA) from the FDA for its Alinity m Resp-4-Plex molecular assay, a combination test for SARS-CoV-2, Influenza A and B, and respiratory syncytial virus (RSV).
The test uses either an anterior nasal or nasopharyngeal swab collected by a healthcare provider or an anterior nasal swab self-collected at a healthcare location for patients suspected of COVID-19 infection.
The assay runs on the company’s Alinity m system, a polymerase chain reaction (PCR) platform that offers a turnaround time for assays of less than 115 minutes.
Upcoming Events
-
21Oct